Literature DB >> 27648358

Targeting PCDH20 gene by microRNA-122 confers 5-FU resistance in hepatic carcinoma.

Wei Wang1, Wen Bin Liu2, Da Bing Huang1, Wei Jia1, Chu Shu Ji1, Bing Hu1.   

Abstract

Drug resistance is one of the main hurdles for the successful treatment of hepatic carcinoma. However, the detailed mechanisms underlying resistance remain largely unknown and therapeutic approaches are limited. In the present study, we show that miR-122 confers resistance to 5-fluorouracil induced hepatocellular carcinoma cell apoptosis in vitro and reduces the potency of 5-fluorouracil in the inhibition of tumor growth in a mouse xenograft model in vivo. Further studies indicate that miR-122 modulates drug resistance through down-regulation of expression of PCDH20, which belongs to the protocadherin gene family and negatively regulates Akt activation. Knockdown of PCDH20 expression increases Akt phosphorylation, which leads to elevated mTOR activity and enhanced 5-fluorouracil resistance; whereas rescue of PCDH20 expression in miR-122-expressing cells decreases Akt and mTOR phosphorylation, re-sensitizing hepatocellular carcinoma cell to 5-fluorouracil induced apoptosis. Moreover, a specific and potent Akt inhibitor reverses miR-122-conferred 5-fluorouracil resistance. These findings indicate that the miR-122/PCDH20/Akt/mTOR signaling axis has an important role in mediating response to chemotherapy in human hepatocellular carcinoma. A major implication of our study is that inhibition of miR-122 or restoration of PCDH20 expression may have significant therapeutic potential to overcome drug resistance in hepatocellular carcinoma and that the combined use of an Akt inhibitor with 5-fluorouracil may increase efficacy in liver cancer treatment.

Entities:  

Keywords:  5-FU; PCDH20; hepatic carcinoma; microRNA-122

Year:  2016        PMID: 27648358      PMCID: PMC5004072     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  30 in total

1.  MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer.

Authors:  Regalla Kumarswamy; Giridhar Mudduluru; Paolo Ceppi; Santoshi Muppala; Miroslaw Kozlowski; Jacek Niklinski; Mauro Papotti; Heike Allgayer
Journal:  Int J Cancer       Date:  2011-08-08       Impact factor: 7.396

Review 2.  Micro-RNAs: The new potential biomarkers in cancer diagnosis, prognosis and cancer therapy.

Authors:  B Mansoori; A Mohammadi; S Shirjang; B Baradaran
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2015-10-16       Impact factor: 1.770

Review 3.  Serum markers of hepatocellular carcinoma.

Authors:  H C Spangenberg; R Thimme; H E Blum
Journal:  Semin Liver Dis       Date:  2006-11       Impact factor: 6.115

4.  Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation.

Authors:  J Ying; H Li; T J Seng; C Langford; G Srivastava; S W Tsao; T Putti; P Murray; A T C Chan; Q Tao
Journal:  Oncogene       Date:  2006-02-16       Impact factor: 9.867

5.  Knockdown of flotillin-2 impairs the proliferation of breast cancer cells through modulation of Akt/FOXO signaling.

Authors:  Gui'e Xie; Jinlong Li; Jingsong Chen; Xuewei Tang; Shaoqing Wu; Can Liao
Journal:  Oncol Rep       Date:  2015-03-03       Impact factor: 3.906

6.  Up-regulation of microRNA-302a inhibited the proliferation and invasion of colorectal cancer cells by regulation of the MAPK and PI3K/Akt signaling pathways.

Authors:  Zhi-Jiang Wei; Ming-Ling Tao; Wei Zhang; Guo-Da Han; Zhong-Cheng Zhu; Zhi-Gang Miao; Jian-Ye Li; Zhan-Bing Qiao
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

7.  The response of Golgi protein 73 to transcatheter arterial chemoembolization in patients with hepatocellular carcinoma may relate to the influence of certain chemotherapeutics.

Authors:  Jie Pan; Ye-Fan Zhang; Hua-Yu Yang; Hai-Feng Xu; Xin Lu; Xin-Ting Sang; Shou-Xian Zhong; Yi-Lei Mao
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2015-08

8.  Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU.

Authors:  Xin Li; Jie Yu; Malcolm V Brock; Qian Tao; James G Herman; Ping Liang; Mingzhou Guo
Journal:  Oncotarget       Date:  2015-05-10

9.  miR-320b suppresses cell proliferation by targeting c-Myc in human colorectal cancer cells.

Authors:  Hantao Wang; Fuao Cao; Xu Li; Hua Miao; Jifu E; Junjie Xing; Chuan-Gang Fu
Journal:  BMC Cancer       Date:  2015-10-20       Impact factor: 4.430

10.  miR-122 regulates tumorigenesis in hepatocellular carcinoma by targeting AKT3.

Authors:  Rounak Nassirpour; Pramod P Mehta; Min-Jean Yin
Journal:  PLoS One       Date:  2013-11-07       Impact factor: 3.240

View more
  7 in total

1.  A Genomic Signature Reflecting Fibroblast Infiltration Into Gastric Cancer Is Associated With Prognosis and Treatment Outcomes of Immune Checkpoint Inhibitors.

Authors:  Yi Lu; Dan Li; Yixin Cao; Leqian Ying; Qing Tao; Fen Xiong; Zhangmin Hu; Yufei Yang; Xuehan Qiao; Chen Peng; Dongqin Zhu; Deqiang Wang; Xiaoqin Li
Journal:  Front Cell Dev Biol       Date:  2022-04-26

2.  Low Expression of Protocadherin-8 Promotes the Progression of Ovarian Cancer.

Authors:  Yuan Cao; Yan Yu; Xiaolong Chen; Fang Ren; Ruitao Zhang; Yanyan Jia; Zhigang Ren; Ranran Sun; Juan Li; Huirong Shi
Journal:  Int J Gynecol Cancer       Date:  2018-02       Impact factor: 3.437

3.  miR-122 Inhibits Hepatocarcinoma Cell Progression by Targeting LMNB2.

Authors:  Xiao-Na Li; Hong Yang; Tao Yang
Journal:  Oncol Res       Date:  2019-09-26       Impact factor: 5.574

4.  CDK Inhibition Reverses Acquired 5-Fluorouracil Resistance in Hepatocellular Carcinoma Cells.

Authors:  Yiyi Pu; Dongmei Yan; Linglan Tu; Liyan Cheng; Jie Yu; Zhuduo Li; Xiaoliang Zheng; Xinbao Wang
Journal:  Dis Markers       Date:  2022-03-11       Impact factor: 3.434

Review 5.  Protocadherin gamma C3: a new player in regulating vascular barrier function.

Authors:  Victoria Kaupp; Kinga G Blecharz-Lang; Christina Dilling; Patrick Meybohm; Malgorzata Burek
Journal:  Neural Regen Res       Date:  2023-01       Impact factor: 6.058

6.  miR-122 and hepatocellular carcinoma: from molecular biology to therapeutics.

Authors:  Xiao Fu; George A Calin
Journal:  EBioMedicine       Date:  2018-10-15       Impact factor: 8.143

Review 7.  LncRNAs in HCV Infection and HCV-Related Liver Disease.

Authors:  Juan P Unfried; P Fortes
Journal:  Int J Mol Sci       Date:  2020-03-24       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.